Drug Trial Radar · NCT00004817
Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures
Last checked: Nov 19, 2026Latest source record: Jun 24, 2005 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
385
Actual
Start
Feb 1991
Primary completion
Not stated
Sponsor
- Sponsor type
- NIH
- Collaborators
- Harborview Injury Prevention and Research Center
- First posted
- Feb 25, 2000
Design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Who can join
- All sexes, from 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
OBJECTIVES: I. Determine whether treating head injured patients with valproate sodium will reduce the risk of developing seizures as a result of the head injury. II. Determine the safety of valproate, the appropriate dose, and the effect valproate may have on the recovery of the brain's ability to compute numbers, solve problems, remember information, and control the movement of limbs after head injury.
Conditions
- Post-Traumatic Seizure Disorder
- Head Injuries
Interventions
phenytoinDrug
valproate sodiumDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.